Madhukar Trivedi

List of Publications by Year
in descending order

693 papers	59,567 citations	1301 109 h-index	1461 220 g-index
719 all docs	719 docs citations	719 times ranked	33910 citing authors

#	Article	IF	Citations
1	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1905-1917.	7.2	4,241
2	Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. American Journal of Psychiatry, 2006, 163, 28-40.	7.2	3,206
3	The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 2003, 54, 573-583.	1.3	2,981
4	The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychological Medicine, 1996, 26, 477-486.	4.5	1,802
5	A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. New England Journal of Medicine, 2000, 342, 1462-1470.	27.0	1,188
6	Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression. New England Journal of Medicine, 2006, 354, 1231-1242.	27.0	934
7	Exercise treatment for depression. American Journal of Preventive Medicine, 2005, 28, 1-8.	3.0	932
8	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Contemporary Clinical Trials, 2004, 25, 119-142.	1.9	898
9	Medication Augmentation after the Failure of SSRIs for Depression. New England Journal of Medicine, 2006, 354, 1243-1252.	27.0	897
10	The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychological Medicine, 2004, 34, 73-82.	4.5	822
11	Harmonization of cortical thickness measurements across scanners and sites. NeuroImage, 2018, 167, 104-120.	4.2	790
12	Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report. American Journal of Psychiatry, 2008, 165, 342-351.	7.2	741
13	Physical activity dose-response effects on outcomes of depression and anxiety. Medicine and Science in Sports and Exercise, 2001, 33, S587-S597.	0.4	597
14	Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology, 2006, 31, 1841-1853.	5.4	572
15	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. American Journal of Psychiatry, 2019, 176, 428-438.	7.2	557
16	The STAR*D project results: A comprehensive review of findings. Current Psychiatry Reports, 2007, 9, 449-459.	4.5	554
17	Remissions in Maternal Depression and Child Psychopathology. JAMA - Journal of the American Medical Association, 2006, 295, 1389.	7.4	539
18	A Comparison of Lithium and T_3 Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1519-1530.	7.2	526

#	Article	IF	Citations
19	What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. Psychiatric Services, 2009, 60, 1439-1445.	2.0	508
20	The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 156-165.	1.4	478
21	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. JAMA Psychiatry, 2019, 76, 893.	11.0	472
22	Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry,the, 2016, 3, 243-250.	7.4	469
23	Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STARâˆ—D) study. Psychiatric Clinics of North America, 2003, 26, 457-494.	1.3	456
24	Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment. American Journal of Human Genetics, 2006, 78, 804-814.	6.2	434
25	Effect of Hypericum perforatum (St John's Wort) in Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2002, 287, 1807.	7.4	417
26	Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). International Journal of Neuropsychopharmacology, 2019, 22, 616-630.	2.1	404
27	Effect of Age at Onset on the Course of Major Depressive Disorder. American Journal of Psychiatry, 2007, 164, 1539-1546.	7.2	393
28	The pattern of sensory processing abnormalities in autism. Autism, 2006, 10, 480-494.	4.1	373
29	Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychological Medicine, 2010, 40, 41-50.	4.5	366
30	Gender differences in depression: Findings from the STAR*D study. Journal of Affective Disorders, 2005, 87, 141-150.	4.1	359
31	Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychological Medicine, 2004, 34, 1299-1308.	4.5	352
32	An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report. Biological Psychiatry, 2006, 59, 493-501.	1.3	344
33	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. American Journal of Psychiatry, 2011, 168, 689-701.	7.2	329
34	Inverse Association between Physical Inactivity and Mental Health in Men and Women. Medicine and Science in Sports and Exercise, 2006, 38, 173-178.	0.4	312
35	Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1531-1541.	7.2	300
36	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 739-752.	7.2	297

#	Article	IF	Citations
37	Statistical harmonization corrects site effects in functional connectivity measurements from multiâ€site fMRI data. Human Brain Mapping, 2018, 39, 4213-4227.	3.6	295
38	Time for united action on depression: a Lancetâ€"World Psychiatric Association Commission. Lancet, The, 2022, 399, 957-1022.	13.7	292
39	Clinical Results for Patients With Major Depressive Disorder in theTexas Medication Algorithm Project. Archives of General Psychiatry, 2004, 61, 669.	12.3	284
40	Aripiprazole Augmentation in Major Depressive Disorder: <i>A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants</i>. CNS Spectrums, 2009, 14, 197-206.	1.2	254
41	Agomelatine in the Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 2010, 71, 616-626.	2.2	245
42	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry, 2020, 25, 1592-1603.	7.9	235
43	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1161-1172.	7.2	233
44	Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Molecular Psychiatry, 2020, 25, 339-350.	7.9	228
45	Self-Rated Global Measure of the Frequency, Intensity, and Burden of Side Effects. Journal of Psychiatric Practice, 2006, 12, 71-79.	0.7	227
46	Psychotherapy and Medication in the Treatment of Adult and Geriatric Depression. Journal of Clinical Psychiatry, 2005, 66, 455-468.	2.2	227
47	Cognitive dysfunction in unipolar depression: Implications for treatment. Journal of Affective Disorders, 2014, 152-154, 19-27.	4.1	221
48	GABAB Receptors, Schizophrenia and Sleep Dysfunction. CNS Drugs, 2009, PAP, 627-47.	5.9	220
49	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. Journal of Psychiatric Research, 2016, 78, 11-23.	3.1	216
50	Identifying Predictors, Moderators, and Mediators of Antidepressant Response in Major Depressive Disorder: Neuroimaging Approaches. American Journal of Psychiatry, 2015, 172, 124-138.	7.2	214
51	Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. Journal of Affective Disorders, 2005, 87, 43-55.	4.1	210
52	Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Comprehensive Psychiatry, 2008, 49, 238-246.	3.1	209
53	Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report. American Journal of Psychiatry, 2009, 166, 599-607.	7.2	209
54	Association Between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients With Major Depression. Archives of General Psychiatry, 2007, 64, 783.	12.3	208

#	Article	IF	Citations
55	Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination. Biological Psychiatry, 2002, 51, 123-133.	1.3	204
56	Reevaluating the Efficacy and Predictability of Antidepressant Treatments. JAMA Psychiatry, 2017, 74, 370.	11.0	203
57	Sensory correlations in autism. Autism, 2007, 11, 123-134.	4.1	199
58	Association Between Major Depressive Episodes in Patients With Chronic Kidney Disease and Initiation of Dialysis, Hospitalization, or Death. JAMA - Journal of the American Medical Association, 2010, 303, 1946.	7.4	193
59	MAOIs in the Contemporary Treatment of Depression. Neuropsychopharmacology, 1995, 12, 185-219.	5.4	190
60	Cognitive Behavioral Analysis System of Psychotherapy and Brief Supportive Psychotherapy for Augmentation of Antidepressant Nonresponse in Chronic Depression<subtitle>The REVAMP Trial</subtitle><alt-title>Augmentation With CBASP and BSP for Depression</alt-title>. Archives of General Psychiatry, 2009, 66, 1178.	12.3	189
61	The Montgomery Ã„sberg and the Hamilton ratings of depression: A comparison of measures. European Neuropsychopharmacology, 2006, 16, 601-611.	0.7	183
62	Screening and Management of Depression in Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 73, 1827-1845.	2.8	182
63	Exercise as an Augmentation Treatment for Nonremitted Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, 677-684.	2.2	177
64	The Texas Medication Algorithm Project. Journal of Clinical Psychiatry, 1999, 60, 142-156.	2.2	174
65	The STAR*D study: treating depression in the real world.. Cleveland Clinic Journal of Medicine, 2008, 75, 57-66.	1.3	172
66	Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?. Neuropsychopharmacology, 1994, 11, 33-43.	5.4	171
67	Children of Depressed Mothers 1 Year After the Initiation of Maternal Treatment: Findings From the STAR*D-Child Study. American Journal of Psychiatry, 2008, 165, 1136-1147.	7.2	169
68	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1161.	7.2	167
69	Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant Medication. Journal of Clinical Psychopharmacology, 2011, 31, 180-186.	1.4	166
70	Sex differences in response to citalopram: A STARâˆ—D report. Journal of Psychiatric Research, 2009, 43, 503-511.	3.1	164
71	Defining and Measuring Functional Recovery from Depression. CNS Drugs, 2010, 24, 267-284.	5.9	163
72	Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: Results of the BRITE-MD study. Psychiatry Research, 2009, 169, 124-131.	3.3	162

#	Article	IF	Citations
73	Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatrica Scandinavica, 2005, 112, 425-433.	4.5	157
74	An electroencephalographic signature predicts antidepressant response in major depression. Nature Biotechnology, 2020, 38, 439-447.	17.5	157
75	Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Molecular Psychiatry, 2013, 18, 1119-1124.	7.9	156
76	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology, 2017, 78, 105-113.	2.7	155
77	Selecting Among Second-Step Antidepressant Medication Monotherapies. Archives of General Psychiatry, 2008, 65, 870.	12.3	152
78	Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. American Journal of Psychiatry, 2016, 173, 499-508.	7.2	151
79	Childhood trauma history is linked to abnormal brain connectivity in major depression. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8582-8590.	7.1	151
80	Children of Depressed Mothers 1 Year After Remission of Maternal Depression: Findings From the STAR*D-Child Study. American Journal of Psychiatry, 2011, 168, 593-602.	7.2	149
81	What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension. Canadian Journal of Psychiatry, 2006, 51, 823-835.	1.9	148
82	Texas Children's Medication Algorithm Project: Update From Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 667-686.	0.5	146
83	Exercise as an Augmentation Strategy for Treatment of Major Depression. Journal of Psychiatric Practice, 2006, 12, 205-213.	0.7	145
84	Strengthening clinical effectiveness trials: Equipoise-stratified randomization. Biological Psychiatry, 2001, 50, 792-801.	1.3	144
85	Measurement-Based Care in Psychiatric Practice. Journal of Clinical Psychiatry, 2011, 72, 1136-1143.	2.2	142
86	Slow-wave activity in NREM sleep: sex and age effects in depressed outpatients and healthy controls. Psychiatry Research, 2000, 95, 201-213.	3.3	140
87	Chronic Depression. Archives of General Psychiatry, 2005, 62, 513.	12.3	139
88	Bupropion and Naltrexone in Methamphetamine Use Disorder. New England Journal of Medicine, 2021, 384, 140-153.	27.0	139
89	Factors Associated With Health-Related Quality of Life Among Outpatients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2006, 67, 185-195.	2.2	139
90	Relationship between objective and subjective sleep measures in depressed patients and healthy controls. Depression and Anxiety, 1997, 5, 97-102.	4.1	136

#	Article	IF	Citations
91	Early adversity in chronic depression: clinical correlates and response to pharmacotherapy. Depression and Anxiety, 2009, 26, 701-710.	4.1	136
92	Test–retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. Human Brain Mapping, 2015, 36, 3472-3485.	3.6	136
93	Dream recall and major depression: A preliminary report.. Dreaming, 1995, 5, 189-198.	0.5	135
94	Maximizing the Adequacy of Medication Treatment in Controlled Trials and Clinical Practice: STAR*D Measurement-Based Care. Neuropsychopharmacology, 2007, 32, 2479-2489.	5.4	135
95	Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression. Neuropsychopharmacology, 1999, 20, 226-247.	5.4	132
96	Predictors of Attrition During Initial (Citalopram) Treatment for Depression: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 1189-1197.	7.2	129
97	Association Between Treatment-Emergent Suicidal Ideation With Citalopram and Polymorphisms Near Cyclic Adenosine Monophosphate Response Element Binding Protein in the STAR*D Study. Archives of General Psychiatry, 2007, 64, 689.	12.3	128
98	Clinical Evidence and Potential Neurobiological Underpinnings of Unresolved Symptoms of Depression. Journal of Clinical Psychiatry, 2008, 69, 246-258.	2.2	128
99	Benzodiazepines as antidepressants: Does GABA play a role in depression?. Biological Psychiatry, 1995, 38, 578-591.	1.3	126
100	Insomnia in Patients With Depression: <i>A STAR*D Report</i>. CNS Spectrums, 2010, 15, 394-404.	1.2	125
101	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression. JAMA Psychiatry, 2018, 75, 547.	11.0	125
102	Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome. Drug and Alcohol Dependence, 2009, 99, 248-260.	3.2	124
103	Concise Health Risk Tracking Scale. Journal of Clinical Psychiatry, 2011, 72, 757-764.	2.2	124
104	Children of Currently Depressed Mothers. Journal of Clinical Psychiatry, 2006, 67, 126-136.	2.2	123
105	Cognitive-Behavioral Analysis System of Psychotherapy as a Maintenance Treatment for Chronic Depression.. Journal of Consulting and Clinical Psychology, 2004, 72, 681-688.	2.0	122
106	Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Research, 2004, 129, 127-140.	3.3	121
107	Inflammation, Obesity, and Metabolic Syndrome in Depression. Journal of Clinical Psychiatry, 2014, 75, e1428-e1432.	2.2	120
108	Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder. Archives of General Psychiatry, 2010, 68, 351.	12.3	118

#	Article	IF	Citations
109	Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. Journal of Affective Disorders, 2018, 233, 3-14.	4.1	116
110	The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 1999, 38, 1442-1454.	0.5	115
111	Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients. Neuropsychopharmacology, 2005, 30, 405-416.	5.4	115
112	Sulfhydryl-Reactive Metals in Autism. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2007, 70, 715-721.	2.3	113
113	Depression, IV: STAR*D Treatment Trial for Depression. American Journal of Psychiatry, 2003, 160, 237-237.	7.2	109
114	Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. General Hospital Psychiatry, 2004, 26, 421-429.	2.4	109
115	Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Research, 2009, 169, 132-138.	3.3	109
116	Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. Psychological Medicine, 2019, 49, 1118-1127.	4.5	109
117	The link between depression and physical symptoms. Primary Care Companion To the Journal of Clinical Psychiatry, 2004, 6, 12-6.	0.6	109
118	Comparison of Self-Report and Clinician Ratings on Two Inventories of Depressive Symptomatology. Psychiatric Services, 2006, 57, 829-837.	2.0	106
119	Complementary and Alternative Medicine in Major Depressive Disorder. Journal of Clinical Psychiatry, 2010, 71, 669-681.	2.2	106
120	Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System With Antidepressant Treatment Response. Archives of General Psychiatry, 2010, 67, 369.	12.3	105
121	Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents. International Journal of Methods in Psychiatric Research, 2010, 19, 185-194.	2.1	104
122	Increase in Work Productivity of Depressed Individuals With Improvement in Depressive Symptom Severity. American Journal of Psychiatry, 2013, 170, 633-641.	7.2	104
123	Medication Treatment for the Severely and Persistently Mentally Ill. Journal of Clinical Psychiatry, 1999, 60, 284-291.	2.2	102
124	Identification of psychiatric disorder subtypes from functional connectivity patterns in resting-state electroencephalography. Nature Biomedical Engineering, 2021, 5, 309-323.	22.5	100
125	Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. International Clinical Psychopharmacology, 2009, 24, 133-138.	1.7	99
126	Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development. Journal of Clinical Psychiatry, 2010, 71, e1-e21.	2.2	99

#	Article	IF	Citations
127	Evidence-Based Recommendations for the Prescription of Exercise for Major Depressive Disorder. Journal of Psychiatric Practice, 2013, 19, 204-212.	0.7	99
128	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence. JAMA - Journal of the American Medical Association, 2017, 318, 1876.	7.4	99
129	The Effects of Nefazodone on Sleep Architecture in Depression. Neuropsychopharmacology, 1994, 10, 123-127.	5.4	97
130	Health-related quality of life in depression: a STAR*D report. Annals of Clinical Psychiatry, 2010, 22, 43-55.	0.6	97
131	Symptom features of postpartum depression: are they distinct?. Depression and Anxiety, 2008, 25, 20-26.	4.1	96
132	The Effects of Psychotherapy, Nefazodone, and Their Combination on Subjective Assessment of Disturbed Sleep in Chronic Depression. Sleep, 2003, 26, 130-136.	1.1	95
133	Brief Psychiatric Rating Scale Expanded Version: How do new items affect factor structure?. Psychiatry Research, 2005, 135, 217-228.	3.3	94
134	One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biological Psychiatry, 2004, 56, 46-53.	1.3	93
135	The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study. Journal of Clinical Psychiatry, 2007, 68, 1246-1256.	2.2	93
136	Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional Analysis. Annals of Family Medicine, 2007, 5, 126-134.	1.9	92
137	Measurement-based care for refractory depression: A clinical decision support model for clinical research and practice. Drug and Alcohol Dependence, 2007, 88, S61-S71.	3.2	92
138	Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D. Journal of General Internal Medicine, 2008, 23, 551-560.	2.6	92
139	Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study. Neuropsychopharmacology, 2008, 33, 2810-2819.	5.4	92
140	Texas Medication Algorithm Project, Phase 3 (TMAP-3). Journal of Clinical Psychiatry, 2003, 64, 357-369.	2.2	92
141	Response to a Selective Serotonin Reuptake Inhibitor (Citalopram) in Major Depressive Disorder With Melancholic Features. Journal of Clinical Psychiatry, 2008, 69, 1847-1855.	2.2	91
142	The DOSE study. Contemporary Clinical Trials, 2002, 23, 584-603.	1.9	89
143	Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STARâžD study. Journal of Affective Disorders, 2009, 117, 63-73.	4.1	88
144	Systematic Use of Patient-Rated Depression Severity Monitoring: Is It Helpful and Feasible in Clinical Psychiatry?. Psychiatric Services, 2008, 59, 1148-1154.	2.0	87

#	Article	IF	Citations
145	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. American Journal of Psychiatry, 2015, 172, 881-891.	7.2	87
146	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder. Journal of Clinical Psychiatry, 2015, 76, 575-582.	2.2	86
147	Psychometric evaluation of the Snaithâ€"Hamilton pleasure scale in adult outpatients with major depressive disorder. International Clinical Psychopharmacology, 2010, 25, 328-333.	1.7	84
148	Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study. Neuropsychopharmacology, 2016, 41, 454-463.	5.4	84
149	Texas Medication Algorithm Project, Phase 3 (TMAP-3). Journal of Clinical Psychiatry, 2003, 64, 370-382.	2.2	84
150	Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort. American Journal on Addictions, 2006, 15, 278-285.	1.4	83
151	Treatment-resistant depression. Journal of Clinical Psychiatry, 2006, 67 Suppl 6, 16-22.	2.2	83
152	Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment. Journal of Youth and Adolescence, 2008, 37, 906-916.	3.5	81
153	Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatrica Scandinavica, 2009, 119, 282-289.	4.5	81
154	Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced) Tj ETQq0 0 0 rgBT /Overlock 10	4.5	81
155	Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure. Journal of Clinical Psychiatry, 2001, 62, 413-420.	2.2	81
156	Development and Implementation of Computerized Clinical Guidelines: Barriers and Solutions. Methods of Information in Medicine, 2002, 41, 435-442.	1.2	80
157	Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals, 2020, 13, 116.	3.8	78
158	The Texas Medication Algorithm Project: Clinical Results for Schizophrenia. Schizophrenia Bulletin, 2004, 30, 627-647.	4.3	77
159	Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?. Journal of Affective Disorders, 2010, 127, 10-18.	4.1	77
160	A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology, 2015, 232, 2061-2070.	3.1	77
161	Prenatal Depression in Women Hospitalized for Obstetric Risk. Journal of Clinical Psychiatry, 2008, 69, 635-643.	2.2	77
162	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. American Journal of Psychiatry, 2020, 177, 143-154.	7.2	76

#	Article	IF	Citations
163	A Computerized Clinical Decision Support System as a Means of Implementing Depression Guidelines. Psychiatric Services, 2004, 55, 879-885.	2.0	75
164	Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries. Journal of Psychiatric Research, 2005, 39, 481-488.	3.1	74
165	Variation in Catechol-O-Methyltransferase Is Associated with Duloxetine Response in a Clinical Trial for Major Depressive Disorder. Biological Psychiatry, 2009, 65, 785-791.	1.3	74
166	Temporal Characteristics of Delta Activity During NREM Sleep in Depressed Outpatients and Healthy Adults: Group and Sex Effects. Sleep, 2000, 23, 1-11.	1.1	73
167	Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression. Psychological Medicine, 2005, 35, 683-692.	4.5	73
168	Pain in depression: STAR*D study findings. Journal of Psychosomatic Research, 2007, 63, 113-122.	2.6	73
169	Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis. Annals of Internal Medicine, 2019, 170, 369.	3.9	73
170	Reduced anti-inflammatory gut microbiota are associated with depression and anhedonia. Journal of Affective Disorders, 2020, 266, 394-401.	4.1	73
171	Tools and Strategies for Ongoing Assessment of Depression. Journal of Clinical Psychiatry, 2009, 70, 26-31.	2.2	73
172	Clinical differences among depressed patients with and without a history of suicide attempts: Findings from the STARâŽD trial. Journal of Affective Disorders, 2007, 97, 77-84.	4.1	71
173	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug and Alcohol Dependence, 2010, 107, 161-170.	3.2	71
174	Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology, 2007, 32, 843-853.	2.7	70
175	Randomized, Placebo-Controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biological Psychiatry, 2003, 54, 806-817.	1.3	69
176	What predicts attrition in second step medication treatments for depression?: a STAR*D Report. International Journal of Neuropsychopharmacology, 2009, 12, 459.	2.1	69
177	Barriers to implementation of a computerized decision support system for depression: an observational report on lessons learned in "real world" clinical settings. BMC Medical Informatics and Decision Making, 2009, 9, 6.	3.0	69
178	Acceptability of Second-Step Treatments to Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 753-760.	7.2	68
179	Chronic forms of major depression are still undertreated in the 21st century: Systematic assessment of 801 patients presenting for treatment. Journal of Affective Disorders, 2008, 110, 55-61.	4.1	68
180	Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression. Journal of Psychiatric Research, 2011, 45, 1301-1306.	3.1	68

#	Article	IF	Citations
181	A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of Vortioxetine in Adults With Major Depressive Disorder. Journal of Clinical Psychiatry, 2015, 76, 583-591.	2.2	68
182	The History and Current State of Antidepressant Clinical Trial Design. Journal of Clinical Psychiatry, 2008, 69, 1513-1528.	2.2	68
183	Family history of mood disorder and characteristics of major depressive disorder: A STARâˆ—D (sequenced treatment alternatives to relieve depression) study. Journal of Psychiatric Research, 2007, 41, 214-221.	3.1	67
184	Treating Depression to Remission. Psychiatric Annals, 1995, 25, 704-709.	0.1	67
185	TREAD: TReatment with Exercise Augmentation for Depression: study rationale and design. Clinical Trials, 2006, 3, 291-305.	1.6	66
186	Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Review of Neurotherapeutics, 2009, 9, 975-984.	2.8	65
187	Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial. European Neuropsychopharmacology, 2012, 22, 183-199.	0.7	65
188	Prevalence and Clinical Correlates of Irritability in Major Depressive Disorder. Journal of Clinical Psychiatry, 2005, 66, 159-166.	2.2	65
189	A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. General Hospital Psychiatry, 2005, 27, 87-96.	2.4	62
190	Preadult onset vs. adult onset of major depressive disorder: a replication study. Acta Psychiatrica Scandinavica, 2007, 115, 196-205.	4.5	62
191	Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder. Neuropsychopharmacology, 2014, 39, 1388-1398.	5.4	61
192	Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. Neuropsychopharmacology, 2018, 43, 2221-2230.	5.4	61
193	Treatment strategies to improve and sustain remission in major depressive disorder. Dialogues in Clinical Neuroscience, 2008, 10, 377-384.	3.7	61
194	Remission of Maternal Depression: Relations to Family Functioning and Youth Internalizing and Externalizing Symptoms. Journal of Clinical Child and Adolescent Psychology, 2008, 37, 714-724.	3.4	60
195	Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. Brain, Behavior, and Immunity, 2017, 66, 103-110.	4.1	60
196	Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation. International Journal of Molecular Sciences, 2018, 19, 233.	4.1	60
197	Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. International Clinical Psychopharmacology, 1999, 14, 19-28.	1.7	59
198	Prospective, randomized, doubleâ€blind assessment of topical bakuchiol and retinol for facial photoageing. British Journal of Dermatology, 2019, 180, 289-296.	1.5	58

#	Article	IF	Citations
199	Identification of a Signaling Mechanism by Which the Microbiome Regulates Th17 Cell-Mediated Depressive-Like Behaviors in Mice. American Journal of Psychiatry, 2020, 177, 974-990.	7.2	58
200	Concise Associated Symptoms Tracking Scale. Journal of Clinical Psychiatry, 2011, 72, 765-774.	2.2	58
201	Effects of Fluoxetine on the Polysomnogram in Outpatients with Major Depression. Neuropsychopharmacology, 1999, 20, 447-459.	5.4	57
202	Suicidality and Risk of Suicideâ€"Definition, Drug Safety Concerns, and a Necessary Target for Drug Development. Journal of Clinical Psychiatry, 2010, 71, 1040-1046.	2.2	57
203	Fluoxetine and Oculomotor Activity during Sleep in Depressed Patients. Neuropsychopharmacology, 1995, 12, 159-165.	5.4	56
204	Clinical Features of Depression in Outpatients With and Without Co-Occurring General Medical Conditions in STAR*D. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 7-15.	0.6	56
205	Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addictive Behaviors, 2012, 37, 1046-1053.	3.0	55
206	Ethnicity/Race and Outcome in the Treatment of Depression. Medical Care, 2007, 45, 1043-1051.	2.4	54
207	Epidemiology of Nonfatal Deliberate Selfâ€"Harm in the United States as Described in Three Medical Databases. Suicide and Life-Threatening Behavior, 2006, 36, 192-212.	1.9	53
208	Exercise in the treatment of depression. Current Psychiatry Reports, 2009, 11, 466-472.	4.5	53
209	Functional Connectivity of Brain Structures Correlates with Treatment Outcome in Major Depressive Disorder. Frontiers in Psychiatry, 2011, 2, 7.	2.6	53
210	Dose-dependent changes in cognitive function with exercise augmentation for major depression: Results from the TREAD study. European Neuropsychopharmacology, 2015, 25, 248-256.	0.7	53
211	Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder. Journal of Clinical Psychiatry, 2017, 78, 1075-1082.	2.2	53
212	Do Bupropion SR and Sertraline Differ in Their Effects on Anxiety in Depressed Patients?. Journal of Clinical Psychiatry, 2001, 62, 776-781.	2.2	53
213	Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study. Journal of Clinical Psychiatry, 2007, 68, 1014-1023.	2.2	53
214	The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 1999, 60, 142-56.	2.2	53
215	Efficacy of porcine secretin in children with autism and pervasive developmental disorder. Journal of Autism and Developmental Disorders, 2002, 32, 153-160.	2.7	52
216	Examining sensory quadrants in autism. Research in Autism Spectrum Disorders, 2007, 1, 185-193.	1.5	52

#	Article	IF	Citations
217	Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychological Medicine, 2012, 42, 1131-1149.	4.5	52
218	An Integrated Analysis of Olanzapine/Fluoxetine Combination in Clinical Trials of Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2009, 70, 387-396.	2.2	52
219	Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role?. Molecular Psychiatry, 2022, 27, 1095-1102.	7.9	52
220	Effect of 11 September 2001 terrorist attacks in the USA on suicide in areas surrounding the crash sites. British Journal of Psychiatry, 2010, 196, 359-364.	2.8	51
221	Predictors of Abstinence: National Institute of Drug Abuse Multisite Buprenorphine/Naloxone Treatment Trial in Opioid-Dependent Youth. Journal of the American Academy of Child and Adolescent Psychiatry, 2011, 50, 1120-1128.	0.5	51
222	Decline in Cardiorespiratory Fitness and Odds of Incident Depression. American Journal of Preventive Medicine, 2012, 43, 361-368.	3.0	51
223	Exercise is an effective treatment for positive valence symptoms in major depression. Journal of Affective Disorders, 2017, 209, 188-194.	4.1	51
224	Sexual Function and Satisfaction in the Treatment of Chronic Major Depression With Nefazodone, Psychotherapy, and Their Combination. Journal of Clinical Psychiatry, 2002, 63, 709-716.	2.2	51
225	Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depression and Anxiety, 2008, 25, E1-E8.	4.1	50
226	Folate and Unipolar Depression. Journal of Alternative and Complementary Medicine, 2008, 14, 277-285.	2.1	50
227	Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.. Journal of Consulting and Clinical Psychology, 2008, 76, 459-467.	2.0	50
228	Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. International Clinical Psychopharmacology, 2008, 23, 161-169.	1.7	50
229	Do atypical features affect outcome in depressed outpatients treated with citalopram?. International Journal of Neuropsychopharmacology, 2010, 13, 15.	2.1	50
230	Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. Psychological Medicine, 2010, 40, 415-424.	4.5	50
231	Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?. Psychological Medicine, 2013, 43, 699-709.	4.5	50
232	A computational analysis of flanker interference in depression. Psychological Medicine, 2015, 45, 2333-2344.	4.5	50
233	Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. Journal of Affective Disorders, 2018, 234, 34-37.	4.1	50
234	Factors Predicting Reduced Antidepressant Response: Experience with the SNRI Duloxetine in Patients with Major Depression. Annals of Clinical Psychiatry, 2008, 20, 209-218.	0.6	49

#	Article	IF	Citations
235	The Youth Aware of Mental Health Intervention: Impact on Help Seeking, Mental Health Knowledge, and Stigma in U.S. Adolescents. Journal of Adolescent Health, 2020, 67, 101-107.	2.5	49
236	Antenatal depression: a rationale for studying exercise. Depression and Anxiety, 2011, 28, 234-242.	4.1	48
237	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. Biological Psychiatry, 2019, 85, 872-880.	1.3	48
238	Effectiveness of Low Doses of Paroxetine Controlled Release in the Treatment of Major Depressive Disorder. Journal of Clinical Psychiatry, 2004, 65, 1356-1364.	2.2	48
239	Symptom Clusters as Predictors of Late Response to Antidepressant Treatment. Journal of Clinical Psychiatry, 2005, 66, 1064-1070.	2.2	48
240	Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. Journal of Psychiatric Research, 2007, 41, 239-246.	3.1	47
241	The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. Menopause, 2010, 17, 828-839.	2.0	47
242	Relationship Between Obesity and Depression. Psychosomatic Medicine, 2013, 75, 863-872.	2.0	47
243	When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. American Journal of Psychiatry, 2018, 175, 1176-1184.	7.2	47
244	Adjunctive Aripiprazole in Major Depressive Disorder. Journal of Clinical Psychiatry, 2008, 69, 1928-1936.	2.2	47
245	Sex differences in the distribution of EEG frequencies during sleep: unipolar depressed outpatients. Journal of Affective Disorders, 1995, 34, 121-129.	4.1	46
246	Demonstrating test–retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response. Psychophysiology, 2017, 54, 34-50.	2.4	46
247	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. American Journal of Psychiatry, 2018, 175, 169-179.	7.2	46
248	Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. Molecular Psychiatry, 2020, 25, 1580-1591.	7.9	46
249	Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline. Neuropsychopharmacology, 2001, 25, 131-138.	5.4	45
250	Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets. Journal of Affective Disorders, 2011, 132, 396-400.	4.1	45
251	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. Journal of Affective Disorders, 2011, 133, 467-476.	4.1	45
252	Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report. Psychological Medicine, 2013, 43, 945-960.	4.5	45

#	Article	IF	Citations
253	Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder. JAMA Psychiatry, 2020, 77, 397.	11.0	45
254	A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram. Journal of Clinical Psychiatry, 2013, 74, 802-809.	2.2	45
255	Differential Effects of Nefazodone and Cognitive Behavioral Analysis System of Psychotherapy on Insomnia Associated With Chronic Forms of Major Depression. Journal of Clinical Psychiatry, 2002, 63, 493-500.	2.2	45
256	An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder. Journal of Psychiatric Practice, 2008, 14, 271-280.	0.7	44
257	Income and attrition in the treatment of depression: a STAR*D report. Depression and Anxiety, 2009, 26, 622-633.	4.1	44
258	Effect of Antidepressant Medication Treatment on Suicidal Ideation and Behavior in a Randomized Trial. Journal of Clinical Psychiatry, 2011, 72, 1322-1332.	2.2	44
259	Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychological Medicine, 2005, 35, 1695-1706.	4.5	43
260	Pattern recognition analysis of anterior cingulate cortex blood flow to classify depression polarity. British Journal of Psychiatry, 2013, 203, 310-311.	2.8	43
261	Does Duloxetine Improve Cognitive Function Independently of Its Antidepressant Effect in Patients with Major Depressive Disorder and Subjective Reports of Cognitive Dysfunction?. Depression Research and Treatment, 2014, 2014, 1-13.	1.3	43
262	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. Depression and Anxiety, 2016, 33, 56-65.	4.1	43
263	A Computerized Decision Support System for Depression in Primary Care. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 140-146.	0.6	43
264	Prospective trial of equine-assisted activities in autism spectrum disorder. Alternative Therapies in Health and Medicine, 2011, 17, 14-20.	0.0	43
265	Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. Clinical Trials, 2004, 1, 387-398.	1.6	42
266	Depression Outcomes in Psychiatric Clinical Practice: Using a Self-Rated Measure of Depression Severity. Psychiatric Services, 2011, 62, 929-935.	2.0	42
267	Outcomes on the pharmacopsychometric triangle in bupropion€SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatrica Scandinavica, 2012, 125, 342-348.	4.5	42
268	Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model. Addictive Behaviors, 2015, 41, 20-28.	3.0	42
269	Abnormal brain response to cholinergic challenge in chronic encephalopathy from the 1991 Gulf War. Psychiatry Research - Neuroimaging, 2009, 171, 207-220.	1.8	41
270	Stimulant Reduction Intervention using Dosed Exercise (STRIDE) - CTN 0037: Study protocol for a randomized controlled trial. Trials, 2011, 12, 206.	1.6	41

#	Article	IF	Citations
271	Cognitive therapy for anxious depression in STARâŽD: What have we learned?. Journal of Affective Disorders, 2012, 142, 213-218.	4.1	41
272	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. Journal of Psychiatric Research, 2019, 110, 166-171.	3.1	41
273	Dissecting the impact of depression on decision-making. Psychological Medicine, 2020, 50, 1613-1622.	4.5	41
274	Two Trajectories of Depressive Symptom Reduction Throughout Behavioral Activation Teletherapy Among Underserved, Ethnically Diverse, Primary Care Patients: A VitalSign6 Report. Behavior Therapy, 2020, 51, 958-971.	2.4	41
275	A Psychometric Evaluation of the CDRS and MADRS in Assessing Depressive Symptoms in Children. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 1204-1212.	0.5	40
276	Treatment Outcomes for Older Depressed Patients With Earlier Versus Late Onset of First Depressive Episode: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Report. American Journal of Geriatric Psychiatry, 2008, 16, 58-64.	1.2	40
277	Fractional Anisotropy Changes After Several Weeks of Daily Left High-Frequency Repetitive Transcranial Magnetic Stimulation of the Prefrontal Cortex to Treat Major Depression. Journal of ECT, 2011, 27, 5-10.	0.6	40
278	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. American Journal of Psychiatry, 2016, 173, 1196-1204.	7.2	40
279	What moderator characteristics are associated with better prognosis for depression?. Neuropsychiatric Disease and Treatment, 2005, 1, 51-57.	2.2	40
280	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases. Biological Psychiatry, 2007, 62, 1371-1379.	1.3	39
281	Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. Journal of Psychiatric Research, 2011, 45, 96-103.	3.1	39
282	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. Psychotherapy and Psychosomatics, 2018, 87, 285-295.	8.8	39
283	Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. American Journal of Psychiatry, 2019, 176, 358-366.	7.2	39
284	Does the Duration of Index Episode Affect the Treatment Outcome of Major Depressive Disorder?. Journal of Clinical Psychiatry, 2008, 69, 1246-1256.	2.2	39
285	Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 440-447.	0.6	39
286	Tiagabine in Adult Patients With Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 308-316.	1.4	38
287	Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatric Disease and Treatment, 2011, 7, 303.	2.2	37
288	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depression and Anxiety, 2019, 36, 235-243.	4.1	37

#	Article	IF	Citations
289	Definition of treatment-resistant depression – Asia Pacific perspectives. Journal of Affective Disorders, 2019, 245, 626-636.	4.1	37
290	Prevention of Missing Data in Clinical Research Studies. Biological Psychiatry, 2006, 59, 997-1000.	1.3	36
291	Response to vestibular sensory events in autism. Research in Autism Spectrum Disorders, 2007, 1, 67-74.	1.5	36
292	Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the Research Domain Criteria (RDoC). Journal of Affective Disorders, 2014, 163, 18-24.	4.1	36
293	Evaluation of anhedonia with the Snaith–Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder. Journal of Psychiatric Research, 2015, 65, 124-130.	3.1	36
294	Olanzapine/Fluoxetine Combination in Patients With Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2010, 71, 451-462.	2.2	36
295	Diurnal Mood Variation in Outpatients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2007, 68, 1339-1347.	2.2	36
296	Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. Journal of Nuclear Medicine, 2001, 42, 535-42.	5.0	36
297	Clinical and Sociodemographic Characteristics Associated with Suicidal Ideation in Depressed Outpatients. Canadian Journal of Psychiatry, 2013, 58, 113-122.	1.9	35
298	Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral Therapy for End-stage Renal Disease Patients with Depression (ASCEND). Contemporary Clinical Trials, 2016, 47, 1-11.	1.8	35
299	Development and evaluation of a multimodal marker of major depressive disorder. Human Brain Mapping, 2018, 39, 4420-4439.	3.6	35
300	Major Depressive Disorder in Primary Care. Journal of Clinical Psychiatry, 2020, 81, .	2.2	35
301	Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. CNS Spectrums, 2007, 12, 1-27.	1.2	35
302	Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. Journal of Psychiatric Research, 2008, 42, 134-140.	3.1	34
303	Psychosocial outcomes in patients with recurrent major depressive disorder during 2years of maintenance treatment with venlafaxine extended release. Journal of Affective Disorders, 2010, 126, 420-429.	4.1	34
304	Do Menopausal Status and Use of Hormone Therapy Affect Antidepressant Treatment Response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. Journal of Women's Health, 2013, 22, 121-131.	3.3	34
305	IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder. Translational Psychiatry, 2015, 5, e611-e611.	4.8	34
306	Association of T and non-T cell cytokines with anhedonia: Role of gender differences. Psychoneuroendocrinology, 2018, 95, 1-7.	2.7	34

#	Article	IF	Citations
307	Making clinicians lives easier: Guidance on use of the QIDS self-report in place of the MADRS. Journal of Affective Disorders, 2006, 95, 115-118.	4.1	33
308	Diagnostic utility of the Quick Inventory of Depressive Symptomatology (QIDSâ€C₁₆ and) Tj ETQq0 0.0 rgBT /Overlock 10	4.5	33
309	Depression Treatment in Patients With General Medical Conditions: Results From the CO-MED Trial. Annals of Family Medicine, 2012, 10, 23-33.	1.9	33
310	VitalSign6: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression. Pharmaceuticals, 2019, 12, 71.	3.8	33
311	Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study. Journal of Psychiatric Research, 2019, 113, 165-171.	3.1	33
312	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. American Journal of Psychiatry, 2021, 178, 437-446.	7.2	33
313	Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression. Journal of Clinical Psychiatry, 2002, 63, 434-441.	2.2	33
314	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2015, 71, 126-133.	3.1	32
315	Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality. Journal of Affective Disorders, 2018, 235, 45-51.	4.1	32
316	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. World Journal of Biological Psychiatry, 2018, 19, 330-348.	2.6	32
317	Association of Midlife Cardiorespiratory Fitness With Incident Depression and Cardiovascular Death After Depression in Later Life. JAMA Psychiatry, 2018, 75, 911.	11.0	32
318	A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. Annals of Family Medicine, 2019, 17, 326-335.	1.9	32
319	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). Journal of Clinical Psychiatry, 2019, 80, .	2.2	32
320	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments donâ€™t work well enough?. World Journal of Biological Psychiatry, 2021, 22, 483-494.	2.6	32
321	Exercise and Mental Illness. Journal of Clinical Psychiatry, 2012, 73, 960-966.	2.2	32
322	Exercise for Mood and Anxiety Disorders. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 287-294.	0.6	32
323	IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY. Depression and Anxiety, 2016, 33, 870-881.	4.1	31
324	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. American Journal of Nephrology, 2019, 50, 37-47.	3.1	31

#	Article	IF	Citations
325	Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine. Journal of Clinical Psychiatry, 2014, 75, 62-68.	2.2	31
326	A comparison of alternative assessments of depressive symptom severity: a pilot study. Psychiatry Research, 2000, 96, 269-279.	3.3	30
327	Major Depressive Disorder and Comorbid Cardiac Disease: Is There a Depressive Subtype With Greater Cardiovascular Morbidity? Results From the STAR*D Study. Psychosomatics, 2007, 48, 418-425.	2.5	30
328	A Comparison of the $QIDS-C_{16}$, $QIDS-SR_{16}$, and the MADRS in an Adult Outpatient Clinical Sample. CNS Spectrums, 2010, 15, 458-468.	1.2	30
329	Measurement-Based Care for Unipolar Depression. Current Psychiatry Reports, 2011, 13, 446-458.	4.5	30
330	Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial. Psychiatric Services, 2011, 62, 1167-1179.	2.0	30
331	A comparison of structural connectivity in anxious depression versus non-anxious depression. Journal of Psychiatric Research, 2017, 89, 38-47.	3.1	30
332	Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination. International Journal of Neuropsychopharmacology, 2017, 20, 919-927.	2.1	29
333	Brain regulation of emotional conflict predicts antidepressant treatment response for depression. Nature Human Behaviour, 2019, 3, 1319-1331.	12.0	29
334	Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. Molecular Psychiatry, 2020, 25, 1526-1536.	7.9	29
335	Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. Journal of Clinical Psychiatry, 2017, 78, 433-440.	2.2	29
336	Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacology Bulletin, 2003, 37, 73-87.	0.0	29
337	Remission of maternal depression and child symptoms among single mothers. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 962-971.	3.1	28
338	Examining sensory modulation in individuals with autism as compared to community controls. Research in Autism Spectrum Disorders, 2008, 2, 85-94.	1.5	28
339	Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR[*]D trial. Depression and Anxiety, 2009, 26, 612-621.	4.1	28
340	Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder. Depression and Anxiety, 2017, 34, 1116-1122.	4.1	28
341	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. Magnetic Resonance Imaging, 2018, 45, 26-33.	1.8	28
342	Can targeted metabolomics predict depression recovery? Results from the CO-MED trial. Translational Psychiatry, 2019, 9, 11.	4.8	28

#	Article	IF	Citations
343	Discovery and replication of cerebral bloodÂflow differences in major depressive disorder. Molecular Psychiatry, 2020, 25, 1500-1510.	7.9	28
344	Temporal characteristics of delta activity during NREM sleep in depressed outpatients and healthy adults: group and sex effects. Sleep, 2000, 23, 607-17.	1.1	28
345	Development and implementation of computerized clinical guidelines: barriers and solutions. Methods of Information in Medicine, 2002, 41, 435-42.	1.2	28
346	Comparison of Quality of Life Measures in a Depressed Population. Journal of Nervous and Mental Disease, 2007, 195, 219-225.	1.0	27
347	Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. Molecular Psychiatry, 2014, 19, 962-964.	7.9	27
348	Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale. International Journal of Neuropsychopharmacology, 2018, 21, 325-332.	2.1	27
349	Implementing Guidelines and Systems of Care. Journal of Psychiatric Practice, 1999, 5, 75-86.	0.7	26
350	Catching Up on Health Outcomes: The Texas Medication Algorithm Project. Health Services Research, 2003, 38, 311-331.	2.0	26
351	Characteristics of Insured and Noninsured Outpatients With Depression in STAR*D. Psychiatric Services, 2005, 56, 995-1004.	2.0	26
352	Response to Zhang et al., (2005) Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. Neuron 45, 11â€"16. Neuron, 2005, 48, 702-703.	8.1	26
353	Depression Outcomes of Spanish- and English-Speaking Hispanic Outpatients in STAR*D. Psychiatric Services, 2008, 59, 1273-1284.	2.0	26
354	The impact of diabetes on depression treatment outcomes. General Hospital Psychiatry, 2010, 32, 33-41.	2.4	26
355	What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?. Depression and Anxiety, 2012, 29, 94-101.	4.1	26
356	Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemporary Clinical Trials, 2013, 34, 136-144.	1.8	26
357	Adherence to Antidepressant Combinations and Monotherapy for Major Depressive Disorder. Journal of Psychiatric Practice, 2014, 20, 118-132.	0.7	26
358	ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. Pharmacogenomics Journal, 2015, 15, 332-339.	2.0	26
359	Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. Journal of Affective Disorders, 2016, 206, 17-22.	4.1	26
360	Dysfunctional adaptive immune response in adolescents and young adults with suicide behavior. Psychoneuroendocrinology, 2020, 111, 104487.	2.7	26

#	Article	IF	Citations
361	Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder. Neuropsychopharmacology, 2020, 45, 2147-2154.	5.4	26
362	Childhood maltreatment and impact on clinical features of major depression in adults. Psychiatry Research, 2020, 293, 113412.	3.3	26
363	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. PLoS ONE, 2016, 11, e0167901.	2.5	26
364	Quantitative Electroencephalogram Biomarkers for Predicting Likelihood and Speed of Achieving Sustained Remission in Major Depression. Journal of Clinical Psychiatry, 2013, 74, 51-56.	2.2	26
365	Which Depressed Patients Respond to Nefazodone and When?. Journal of Clinical Psychiatry, 2001, 62, 158-163.	2.2	26
366	Regional cerebral blood flow alterations in unipolar depression. Psychiatry Research - Neuroimaging, 1993, 50, 233-256.	1.8	25
367	Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. Journal of Psychiatric Research, 2004, 38, 583-589.	3.1	25
368	Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 344-352.	0.6	25
369	Identifying Risk for Attrition during Treatment for Depression. Psychotherapy and Psychosomatics, 2009, 78, 372-379.	8.8	25
370	Predictors of Attrition During One Year of Depression Treatment: A Roadmap to Personalized Intervention. Journal of Psychiatric Practice, 2009, 15, 113-124.	0.7	25
371	Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression. Clinical EEG and Neuroscience, 2019, 50, 3-12.	1.7	25
372	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2020, 40, 287-292.	1.4	25
373	Treatment-Resistant Depression: New Therapies on the Horizon. Annals of Clinical Psychiatry, 2003, 15, 59-70.	0.6	25
374	The Impact of Chronic Depression on Acute and Long-Term Outcomes in a Randomized Trial Comparing Selective Serotonin Reuptake Inhibitor Monotherapy Versus Each of 2 Different Antidepressant Medication Combinations. Journal of Clinical Psychiatry, 2012, 73, 967-976.	2.2	25
375	Exercise for Mood and Anxiety Disorders. Journal of Clinical Psychiatry, 2007, 68, 669-676.	2.2	25
376	Major depressive disorder: remission of associated symptoms. Journal of Clinical Psychiatry, 2006, 67 Suppl 6, 27-32.	2.2	25
377	What Have We Learned about Trial Design From NIMH-Funded Pragmatic Trials?. Neuropsychopharmacology, 2010, 35, 2491-2501.	5.4	24
378	REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and design. Psychopharmacology Bulletin, 2008, 41, 5-33.	0.0	24

#	Article	IF	Citations
379	Cost and Effectiveness of Venlafaxine Extended-Release and Selective Serotonin Reuptake Inhibitors in the Acute Phase of Outpatient Treatment for Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2004, 24, 497-506.	1.4	23
380	Diurnal mood variation in outpatients with major depressive disorder. Depression and Anxiety, 2009, 26, 851-863.	4.1	23
381	Brief report: Depression and history of suicide attempts in adults with new-onset Type 2 Diabetes. Psychoneuroendocrinology, 2013, 38, 2810-2814.	2.7	23
382	Modeling Predictors, Moderators and Mediators of Treatment Outcome and Resistance in Depression. Biological Psychiatry, 2013, 74, 2-4.	1.3	23
383	The Clinical Relevance of Self-Reported Premenstrual Worsening of Depressive Symptoms in the Management of Depressed Outpatients: A STAR*D Report. Journal of Women's Health, 2013, 22, 219-229.	3.3	23
384	Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial. Journal of Psychiatric Research, 2017, 94, 1-6.	3.1	23
385	Depression Screening and Measurement-Based Care in Primary Care. Journal of Primary Care and Community Health, 2020, 11, 215013272093126.	2.1	23
386	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. Biological Psychiatry, 2020, 88, 657-667.	1.3	23
387	Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. Acta Psychiatrica Scandinavica, 2021, 143, 253-263.	4.5	23
388	Guidelines for the Diagnosis and Treatment of Depression for Primary Care Physicians. Psychosomatics, 1994, 35, 1-12.	2.5	22
389	Growth hormone response to the GABAB agonist baclofen in major depressive disorder. Psychoneuroendocrinology, 1997, 22, 129-140.	2.7	22
390	Impaired delay and trace eyeblink conditioning performance in major depressive disorder. Journal of Affective Disorders, 2005, 86, 235-245.	4.1	22
391	Depressive Symptoms and Metabolic Syndrome in Preventive Healthcare: The Cooper Center Longitudinal Study. Metabolic Syndrome and Related Disorders, 2010, 8, 451-457.	1.3	22
392	Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: Results from the PREVENT study. Journal of Psychiatric Research, 2011, 45, 412-420.	3.1	22
393	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. Journal of Affective Disorders, 2016, 192, 212-218.	4.1	22
394	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 T 6, 22-30.	1.1	22
395	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. Depression and Anxiety, 2020, 37, 771-783.	4.1	22
396	Treating Depression to Full Remission. Journal of Clinical Psychiatry, 2009, 70, e01.	2.2	22

#	Article	IF	Citations
397	A Pilot Study of an Electronic, Adolescent Version of the Quick Inventory of Depressive Symptomatology. Journal of Clinical Psychiatry, 2007, 68, 1436-1440.	2.2	22
398	Article Commentary: Research Priorities for Expanding access to Methadone Treatment for Opioid use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report. Substance Abuse, 2021, 42, 245-254.	2.3	22
399	Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. Journal of Clinical Psychiatry, 2005, 66, 159-66; quiz 147, 273-4.	2.2	22
400	Early Adverse Events and Attrition in Selective Serotonin Reuptake Inhibitor Treatment. Journal of Clinical Psychopharmacology, 2010, 30, 259-266.	1.4	21
401	Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. International Journal of Neuropsychopharmacology, 2012, 15, 1387-1399.	2.1	21
402	Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. International Journal of Neuropsychopharmacology, 2013, 16, 1733-1744.	2.1	21
403	Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 803-813.	2.2	21
404	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. Journal of Affective Disorders, 2020, 260, 131-139.	4.1	21
405	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). Journal of Psychiatric Research, 2020, 122, 22-32.	3.1	21
406	Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. Journal of Clinical Psychiatry, 2008, 69, 1928-36.	2.2	21
407	Electronic source materials in clinical research: Acceptability and validity of symptom self-rating in major depressive disorder. Journal of Psychiatric Research, 2007, 41, 737-743.	3.1	20
408	Right patient, right treatment, right time: biosignatures and precision medicine in depression. World Psychiatry, 2016, 15, 237-238.	10.4	20
409	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimulation, 2018, 11, 75-84.	1.6	20
410	Frontal theta and posterior alpha in resting EEG: A critical examination of convergent and discriminant validity. Psychophysiology, 2020, 57, e13483.	2.4	20
411	A Systematic Review and Meta-Analysis of Depression and Protein–Energy Wasting in Kidney Disease. Kidney International Reports, 2020, 5, 318-330.	0.8	20
412	MAOIs in the Contemporary Treatment of Depression. Neuropsychopharmacology, 1995, 12, 185-219.	5.4	20
413	Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study. PLoS ONE, 2015, 10, e0126326.	2.5	20
414	Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. Translational Psychiatry, 2021, 11, 513.	4.8	20

#	Article	IF	Citations
415	An Empirical Analysis of Cost Outcomes of the Texas Medication Algorithm Project. Psychiatric Services, 2006, 57, 648-659.	2.0	19
416	Assessing Physicians' Use of Treatment Algorithms: Project IMPACTS Study Design and Rationale. Contemporary Clinical Trials, 2007, 28, 192-212.	1.8	19
417	The Effect of Pain on Outcomes in a Trial of Duloxetine Treatment of Major Depressive Disorder. Annals of Clinical Psychiatry, 2008, 20, 187-193.	0.6	19
418	DATE: Depressed adolescents treated with exercise: Study rationale and design for a pilot study. Mental Health and Physical Activity, 2009, 2, 76-85.	1.8	19
419	Neural Correlates of Successful Response Inhibition in Unmedicated Patients With Late-Life Depression. American Journal of Geriatric Psychiatry, 2012, 20, 1057-1069.	1.2	19
420	Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: A CO-MED report. Journal of Affective Disorders, 2015, 174, 157-164.	4.1	19
421	Culturally adapted depression education and engagement in treatment among Hispanics in primary care: outcomes from a pilot feasibility study. BMC Family Practice, 2019, 20, 140.	2.9	19
422	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. EClinicalMedicine, 2019, 10, 32-41.	7.1	19
423	Harmonized Outcome Measures for Use in Depression Patient Registries and Clinical Practice. Annals of Internal Medicine, 2020, 172, 803-809.	3.9	19
424	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology, 2021, 46, 2266-2277.	5.4	19
425	Family History of Depression and Therapeutic Outcome. Journal of Clinical Psychiatry, 2009, 70, 185-195.	2.2	19
426	A psychometric evaluation of the clinician‐rated Quick Inventory of Depressive Symptomatology (QIDS‐C$_{16}$) in patients with bipolar disorder. International Journal of Methods in Psychiatric Research, 2009, 18, 138-146.	2.1	18
427	Self-rated measure of pain frequency, intensity, and burden: Psychometric properties of a new instrument for the assessment of pain. Journal of Psychiatric Research, 2014, 59, 155-160.	3.1	18
428	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. Journal of Affective Disorders, 2017, 223, 146-152.	4.1	18
429	Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2017, 20, 613-618.	2.1	18
430	Focusing on insomnia symptoms to better understand depression: A STAR*D report. Journal of Affective Disorders, 2020, 260, 183-186.	4.1	18
431	Implementation of the Texas Medication Algorithm Project Patient and Family Education Program. Journal of Clinical Psychiatry, 2006, 67, 1362-1372.	2.2	18
432	A SPECT HMPAO study of regional cerebral blood flow in depressed adolescents and normal controls. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1999, 23, 643-656.	4.8	17

#	Article	IF	Citations
433	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Focus (American Psychiatric Publishing), 2008, 6, 128-142.	0.8	17
434	Indicators of pretreatment suicidal ideation in adults with major depressive disorder. Acta Psychiatrica Scandinavica, 2010, 121, 480-484.	4.5	17
435	Rationale and methods for site selection for a trial using a novel intervention to treat stimulant abuse. Contemporary Clinical Trials, 2012, 33, 29-37.	1.8	17
436	Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings From the EMBARC Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 138-148.	1.5	17
437	Cortical thickness is not associated with current depression in a clinical treatment study. Human Brain Mapping, 2017, 38, 4370-4385.	3.6	17
438	Evaluation of the benefits of exercise on cognition in major depressive disorder. General Hospital Psychiatry, 2017, 49, 19-25.	2.4	17
439	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. Journal of Affective Disorders, 2019, 245, 1070-1078.	4.1	17
440	TARGET JNL: Neuropsychiatric Disease and Treatment Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2333-2345.	2.2	17
441	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. European Neuropsychopharmacology, 2021, 49, 122-132.	0.7	17
442	Predicting Response to the Antidepressant Bupropion Using Pretreatment fMRI. Lecture Notes in Computer Science, 2019, 11843, 53-62.	1.3	17
443	Evaluating and Monitoring Treatment Response in Depression Using Measurement-Based Assessment and Rating Scales. Journal of Clinical Psychiatry, 2013, 74, e14.	2.2	17
444	Comparison of technetium-99m-HMPAO and xenon-133 measurements of regional cerebral blood flow by SPECT. Journal of Nuclear Medicine, 1996, 37, 1735-40.	5.0	17
445	The development of clinical paractice guidelines for the diagnosis and treatment of depression. General Hospital Psychiatry, 1992, 14, 230-236.	2.4	16
446	Family history of completed suicide and characteristics of major depressive disorder: A STARâŽD (sequenced treatment alternatives to relieve depression) study. Journal of Affective Disorders, 2008, 108, 129-134.	4.1	16
447	Changes in Depressive Symptoms and Social Functioning in the Sequenced Treatment Alternatives to Relieve Depression Study. Journal of Nervous and Mental Disease, 2011, 199, 807-810.	1.0	16
448	Assessing anxious features in depressed outpatients. International Journal of Methods in Psychiatric Research, 2011, 20, e69-82.	2.1	16
449	Is C-reactive protein ready for prime time in the selection of antidepressant medications?. Psychoneuroendocrinology, 2017, 84, 206.	2.7	16
450	Feasibility and Acceptability of the Youth Aware of Mental Health (YAM) Intervention in US Adolescents. Archives of Suicide Research, 2020, 24, 269-284.	2.3	16

#	Article	IF	Citations
451	Prevalence and Impact of Obsessive-Compulsive Symptoms in Depression. Journal of Clinical Psychiatry, 2015, 76, 1668-1674.	2.2	16
452	Occipital brain perfusion deficits in children with major depressive disorder. Journal of Nuclear Medicine, 2001, 42, 1059-61.	5.0	16
453	The effectiveness of secretin in the management of autism. Expert Opinion on Pharmacotherapy, 2004, 5, 379-387.	1.8	15
454	A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: A STARâŽD report. Journal of Affective Disorders, 2008, 108, 113-120.	4.1	15
455	The Relationship Between Adverse Events During Selective Serotonin Reuptake Inhibitor Treatment for Major Depressive Disorder and Nonremission in the Suicide Assessment Methodology Study. Journal of Clinical Psychopharmacology, 2011, 31, 31-38.	1.4	15
456	EFFECT OF CONCURRENT SUBSTANCE USE DISORDER ON THE EFFECTIVENESS OF SINGLE AND COMBINATION ANTIDEPRESSANT MEDICATIONS FOR THE TREATMENT OF MAJOR DEPRESSION: AN EXPLORATORY ANALYSIS OF A SINGLE-BLIND RANDOMIZED TRIAL. Depression and Anxiety, 2012, 29, 111-122.	4.1	15
457	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. Journal of Clinical Psychiatry, 2016, 77, 1036-1042.	2.2	15
458	Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. Journal of Affective Disorders, 2016, 200, 156-158.	4.1	15
459	Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. Neuropsychopharmacology, 2019, 44, 2268-2276.	5.4	15
460	Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. Journal of Clinical Psychiatry, 2007, 68, 1339-47.	2.2	15
461	A comparison of alternative assessments of depressive symptom severity: a pilot study. Psychiatry Research, 2000, 95, 55-65.	3.3	14
462	Research staff training in a multisite randomized clinical trial: Methods and recommendations from the stimulant reduction intervention using dosed exercise (STRIDE) trial. Addiction Research and Theory, 2014, 22, 407-415.	1.9	14
463	Childhood Depression Subscales Using Repeated Sessions on Children's Depression Rating Scale â€" Revised (CDRS-R) Scores. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 318-324.	1.3	14
464	Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. Journal of Addiction Medicine, 2016, 10, 236-243.	2.6	14
465	Effects of depression, metabolic syndrome, and cardiorespiratory fitness on mortality: results from the Cooper Center Longitudinal Study. Psychological Medicine, 2017, 47, 2414-2420.	4.5	14
466	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. Journal of Psychiatric Research, 2018, 102, 65-71.	3.1	14
467	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. Journal of Psychopharmacology, 2019, 33, 185-193.	4.0	14
468	Toward a very brief quality of life enjoyment and Satisfaction Questionnaire. Journal of Affective Disorders, 2019, 242, 87-95.	4.1	14

#	Article	IF	Citations
469	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2020, 126, 19-25.	3.1	14
470	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. Neuropsychopharmacology, 2021, 46, 1272-1282.	5.4	14
471	Efficacy of a Behavioral Activation Teletherapy Intervention to Treat Depression and Anxiety in Primary Care VitalSign<sup>6</sup> Program. primary care companion for CNS disorders, The, 2017, 19, .	0.6	14
472	Experiencing bullying's impact on adolescent depression and anxiety: Mediating role of adolescent resilience. Journal of Affective Disorders, 2022, 310, 477-483.	4.1	14
473	Computerizing Medication Algorithms and Decision Support Systems for Major. Journal of Psychiatric Practice, 2000, 6, 237-246.	0.7	13
474	A review of quetiapine in combination with antidepressant therapy in patients with depression. Neuropsychiatric Disease and Treatment, 2007, Volume 3, 855-867.	2.2	13
475	Determining the Primary Endpoint for a Stimulant Abuse Trial: Lessons Learned from STRIDE (CTN 0037). American Journal of Drug and Alcohol Abuse, 2011, 37, 339-349.	2.1	13
476	STimulant Reduction Intervention using Dosed Exercise (STRIDE) â€" Description of the exercise intervention and behavioral program to ensure adherence. Mental Health and Physical Activity, 2012, 5, 175-182.	1.8	13
477	Depression Screening and Education: Options to Reduce Barriers to Treatment (DESEO): protocol for an educational intervention study. BMC Health Services Research, 2016, 16, 322.	2.2	13
478	Improving the identification and treatment of depression in low-income primary care clinics: a qualitative study of providers in the VitalSign6 program. International Journal for Quality in Health Care, 2019, 31, 57-63.	1.8	13
479	Anatomically informed data augmentation for functional MRI with applications to deep learning. , 2020, 11313, .		13
480	Analysis of Suicidality in Pooled Data From 2 Double-Blind, Placebo-Controlled Aripiprazole Adjunctive Therapy Trials in Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, 548-555.	2.2	13
481	Are Depressed Outpatients With and Without a Family History of Substance Use Disorder Different?. Journal of Clinical Psychiatry, 2007, 68, 1931-1938.	2.2	13
482	Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP). Psychopharmacology Bulletin, 1998, 34, 355-9.	0.0	13
483	Consensus guidelines in the treatment of major depressive disorder. Journal of Clinical Psychiatry, 1998, 59 Suppl 20, 73-84.	2.2	13
484	Developing a Neuropsychiatric Functional Brain Imaging Test. Neurocase, 2008, 14, 54-58.	0.6	12
485	Telephone-based assessments to minimize missing data in longitudinal depression trials: A project IMPACTS study report. Contemporary Clinical Trials, 2009, 30, 13-19.	1.8	12
486	How Commonly Used Inclusion and Exclusion Criteria in Antidepressant Registration Trials Affect Study Enrollment. Journal of Psychiatric Practice, 2015, 21, 267-274.	0.7	12

#	Article	IF	Citations
487	Measurement, Education and Tracking in Integrated Care (METRIC): use of a culturally adapted education tool versus standard education to increase engagement in depression treatment among Hispanic patients: study protocol for a randomized control trial. Trials, 2017, 18, 363.	1.6	12
488	Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. Journal of Psychiatric Research, 2018, 102, 207-215.	3.1	12
489	Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. Neuropsychopharmacology, 2018, 43, 2197-2203.	5.4	12
490	Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response. Journal of Affective Disorders, 2019, 256, 8-16.	4.1	12
491	Impact of the COVID-19 pandemic on adults with current and prior depression: initial findings from the longitudinal Texas RAD study. Journal of Affective Disorders, 2021, 294, 103-108.	4.1	12
492	Item response analysis of the inventory of depressive symptomatology. Neuropsychiatric Disease and Treatment, 2006, 2, 557-564.	2.2	12
493	Clinically Relevant Findings from STAR*D. Psychiatric Annals, 2008, 38, .	0.1	12
494	Commentary. Primary Care Companion To the Journal of Clinical Psychiatry, 2006, 8, 291-8.	0.6	12
495	Treatment-resistant depression: new therapies on the horizon. Annals of Clinical Psychiatry, 2003, 15, 59-70.	0.6	12
496	Quantitative EEG amplitude across REM sleep periods in depression: preliminary report. Journal of Psychiatry and Neuroscience, 2002, 27, 40-6.	2.4	12
497	Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response. Biological Psychiatry, 2022, 92, 533-542.	1.3	12
498	Clinicians' Adherence to an Algorithm for Pharmacotherapy of Depression in the Texas Public Mental Health Sector. Psychiatric Services, 2004, 55, 703-705.	2.0	11
499	The Impact of Nonclinical Factors on Care Use for Patients with Depression: A STAR*D Report. CNS Neuroscience and Therapeutics, 2009, 15, 320-332.	3.9	11
500	Power of Automated Algorithms for Combining Time-Line Follow-Back and Urine Drug Screening Test Results in Stimulant-Abuse Clinical Trials. American Journal of Drug and Alcohol Abuse, 2011, 37, 350-357.	2.1	11
501	A health education intervention as the control condition in the CTN-0037 STRIDE multi-site exercise trial: Rationale and description. Mental Health and Physical Activity, 2014, 7, 37-41.	1.8	11
502	Depressive Symptoms and Associated Clinical Characteristics in Outpatients Seeking Community-Based Treatment for Alcohol and Drug Problems. Substance Abuse, 2015, 36, 297-303.	2.3	11
503	Comorbidities and Race/Ethnicity Among Adults with Stimulant Use Disorders in Residential Treatment. Journal of Ethnicity in Substance Abuse, 2015, 14, 79-95.	0.9	11
504	Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders. Psychiatry Research, 2016, 246, 136-141.	3.3	11

#	Article	IF	Citations
505	Pharmacogenomics and Biomarkers of Depression. Handbook of Experimental Pharmacology, 2018, 250, 101-113.	1.8	11
506	<i>The American Journal of Psychiatry</i>â€™s Commitment to Combat Racism, Social Injustice, and Health Care Inequities. American Journal of Psychiatry, 2020, 177, 791-791.	7.2	11
507	The effect of esketamine in patients with treatmentâ€resistant depression with and without comorbid anxiety symptoms or disorder. Depression and Anxiety, 2021, 38, 1120-1130.	4.1	11
508	Reductions in Stress and Depressive Symptoms in Mothers of Substance-Exposed Infants, Participating in a Psychosocial Program. Maternal and Child Health Journal, 2004, 8, 127-136.	1.5	10
509	Factors Associated with Concomitant Psychotropic Drug Use in the Treatment of Major Depression: A STAR*D Report. CNS Spectrums, 2009, 14, 487-498.	1.2	10
510	Pilot investigation into the sickness response to influenza vaccination in adults: Effect of depression and anxiety. General Hospital Psychiatry, 2017, 48, 56-61.	2.4	10
511	VitalSign : Screening, Diagnosis, andÂTreatment of Depression for AdolescentsÂPresenting to Pediatric PrimaryÂand Specialty Care Settings. Journal of the American Academy of Child and Adolescent Psychiatry, 2019, 58, 632-635.	0.5	10
512	Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial. Pharmaceuticals, 2019, 12, 184.	3.8	10
513	Suicidal Ideation and Depression Among Adolescent and Young Adult Cancer Patients. Journal of Adolescent and Young Adult Oncology, 2021, 10, 549-554.	1.3	10
514	Dysfunction of default mode network is associated with active suicidal ideation in youths and young adults with depression: Findings from the T-RAD study. Journal of Psychiatric Research, 2021, 142, 258-262.	3.1	10
515	What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI. Journal of Clinical Psychiatry, 2020, 81, .	2.2	10
516	Growth hormone response to baclofen: a comparison of 10-mg and 20-mg doses in healthy men. Psychiatry Research, 1996, 60, 41-47.	3.3	9
517	Intermediate outcome of medical patients after intensive care. Anaesthesia, 2001, 56, 841-846.	3.8	9
518	A Quality Improvement Process for Implementing the Texas Algorithm for Schizophrenia in Ohio. Psychiatric Services, 2003, 54, 1646-1649.	2.0	9
519	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. Australian and New Zealand Journal of Psychiatry, 2009, 43, 956-967.	2.3	9
520	Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis. General Hospital Psychiatry, 2016, 42, 60-66.	2.4	9
521	Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes. American Journal of Nephrology, 2016, 44, 234-244.	3.1	9
522	Toward a very brief selfâ€report to assess the core symptoms of depression (VQIDSâ€SR$_5$). Acta Psychiatrica Scandinavica, 2017, 135, 548-553.	4.5	9

#	Article	IF	Citations
523	A complier average causal effect analysis of the Stimulant Reduction Intervention using dosed exercise study. Contemporary Clinical Trials Communications, 2018, 10, 1-8.	1.1	9
524	Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure. Value in Health, 2019, 22, 906-915.	0.3	9
525	Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. International Clinical Psychopharmacology, 2020, 35, 313-321.	1.7	9
526	Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study. Journal of Affective Disorders, 2020, 275, 44-47.	4.1	9
527	Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. Depression and Anxiety, 2020, 37, 485-495.	4.1	9
528	Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care. Addiction Science & Clinical Practice, 2021, 16, 12.	2.6	9
529	School Personnel and Parents' Concerns Related to COVID-19 Pandemic's Impact Related to Schools. School Psychology Review, 2021, 50, 519-529.	3.0	9
530	Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial. Biological Psychiatry, 2022, 91, 550-560.	1.3	9
531	Managing depressive disorders in patients with epilepsy. Psychiatry, 2007, 4, 26-34.	0.3	9
532	The Psychopharmacological Treatment of Nonmajor Mood Disorders. , 1997, 25, 146-166.		8
533	Remission and recovery in depression treatment. Drug Development Research, 2005, 65, 335-343.	2.9	8
534	Role of metabolic dysfunction in treatment resistance of major depressive disorder. Neuropsychiatry, 2011, 1, 441-455.	0.4	8
535	Measurement-Based Care in the Treatment of Clinical Depression. Focus (American Psychiatric) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.8	8
536	Racial and ethnic differences in treatment outcomes among adults with stimulant use disorders after a dosed exercise intervention. Journal of Ethnicity in Substance Abuse, 2017, 16, 495-510.	0.9	8
537	Sex-specific differences in the association between body mass index and brain aging in young adults: Findings from the human connectome project. Psychoneuroendocrinology, 2021, 124, 105059.	2.7	8
538	Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management. Current Diabetes Reviews, 2017, 13, 251-262.	1.3	8
539	Remission With Venlafaxine Extended Release or Selective Serotonin Reuptake Inhibitors in Depressed Patients. primary care companion for CNS disorders, The, 2011, 13, .	0.6	8
540	Rationale for Using Exercise in the Treatment of Stimulant Use Disorders. Journal of Global Drug Policy and Practice, 2012, 6, .	0.0	8

#	Article	IF	Citations
541	Algorithm for the treatment of chronic depression. Journal of Clinical Psychiatry, 2001, 62 Suppl 6, 22-9.	2.2	8
542	Socioeconomic Predictors of Treatment Outcomes Among Adults With Major Depressive Disorder. Psychiatric Services, 2022, 73, 965-969.	2.0	8
543	Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). Journal of Psychiatric Research, 2004, 38, 241-248.	3.1	7
544	Feasible Evidence-Based Strategies to Manage Depression in Primary Care. Current Psychiatry Reports, 2012, 14, 370-375.	4.5	7
545	Risk for Partner Victimization and Marital Dissatisfaction Among Chronically Depressed Patients. Journal of Family Violence, 2012, 27, 75-85.	3.3	7
546	Quetiapine XR monotherapy in major depressive disorder. International Clinical Psychopharmacology, 2013, 28, 113-120.	1.7	7
547	Men and women from the STRIDE clinical trial: An assessment of stimulant abstinence symptom severity at residential treatment entry. American Journal on Addictions, 2015, 24, 336-340.	1.4	7
548	An ounce of prevention: A pre-randomization protocol to improve retention in substance use disorder clinical trials. Addictive Behaviors, 2017, 64, 137-142.	3.0	7
549	The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors. BMC Cancer, 2018, 18, 744.	2.6	7
550	Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. International Journal of Neuropsychopharmacology, 2019, 22, 339-348.	2.1	7
551	The Concise Health Risk Tracking Self–Report (CHRT–SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. Depression and Anxiety, 2019, 36, 313-320.	4.1	7
552	Depressive Disorders in HIV/AIDS: A Clinically Focused Narrative Review. Harvard Review of Psychiatry, 2020, 28, 146-158.	2.1	7
553	Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study. Psychiatric Research and Clinical Practice, 2020, 2, 10-18.	2.4	7
554	Association of anger attacks with suicidal ideation in adults with major depressive disorder: Findings from the EMBARC study. Depression and Anxiety, 2021, 38, 57-66.	4.1	7
555	Profiles of depression in a treatment–seeking Hispanic population: Psychometric properties of the Patient Health Questionnaire–9. International Journal of Methods in Psychiatric Research, 2021, 30, e1851.	2.1	7
556	Crisis of Confidence. Journal of Clinical Psychiatry, 2011, 72, e11.	2.2	7
557	Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. Journal of Personalized Medicine, 2022, 12, 412.	2.5	7
558	Quality improvement methods as applied to a multicenter effectiveness trial—STAR*D. Contemporary Clinical Trials, 2005, 26, 95-112.	1.8	6

#	Article	IF	Citations
559	On the invariance of the Stimulant Craving Questionnaire (STCQ) across cocaine and methamphetamine users. Addictive Behaviors, 2015, 42, 144-147.	3.0	6
560	Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression. American Journal of Kidney Diseases, 2020, 75, 457-460.	1.9	6
561	Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. Psychological Medicine, 2022, 52, 2441-2449.	4.5	6
562	Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study. Psychological Medicine, 2020, , 1-9.	4.5	6
563	Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 20-28.	1.5	6
564	Quality of life after response to acute-phase cognitive therapy for recurrent depression. Journal of Affective Disorders, 2021, 278, 218-225.	4.1	6
565	Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life. Journal of Clinical Psychiatry, 2021, 82, .	2.2	6
566	Treating Depression Complicated by Comorbid Medical Illness or Anxiety. Journal of Clinical Psychiatry, 2007, 68, e01.	2.2	6
567	Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 82, .	2.2	6
568	The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials. Translational Psychiatry, 2021, 11, 531.	4.8	6
569	Depression education fotonovela for engagement of Hispanic patients in treatment: a randomized clinical trial. BMC Psychiatry, 2021, 21, 635.	2.6	6
570	Polysomnogram in major depressive and obsessive–compulsive disorders: A preliminary study. Depression, 1994, 2, 297-302.	0.6	5
571	Evaluation of newer treatment interventions for psychotic depression. Current Psychiatry Reports, 2000, 2, 305-309.	4.5	5
572	Dr. Trivedi and Colleagues Reply. American Journal of Psychiatry, 2006, 163, 1293-1294.	7.2	5
573	Screening for depression in a diabetic outpatient population. International Journal of Psychiatry in Clinical Practice, 2007, 11, 268-272.	2.4	5
574	Insured and Non-insured Depressed Outpatients: How Do They Compare?. Annals of Clinical Psychiatry, 2007, 19, 73-82.	0.6	5
575	Sustaining Practice Change One Year After Completion of the National Depression Management Leadership Initiative. Psychiatric Services, 2013, 64, 703-706.	2.0	5
576	Cardiorespiratory fitness and body composition of stimulant users: A baseline analysis of the STRIDE cohort. Journal of Substance Abuse Treatment, 2017, 78, 74-79.	2.8	5

#	Article	IF	Citations
577	A pilot program for implementing mental health screening, assessment, and navigation in a communityâ€based cancer center. Psycho-Oncology, 2018, 27, 683-686.	2.3	5
578	Adiponectin moderates antidepressant treatment outcome in the combining medications to enhance depression outcomes randomized clinical trial. Personalized Medicine in Psychiatry, 2018, 9-10, 1-7.	0.1	5
579	Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. Epilepsy Research, 2018, 146, 50-53.	1.6	5
580	Kynurenine pathway metabolites selectively associate with impaired associative memory function in depression. Brain, Behavior, & Immunity - Health, 2020, 8, 100126.	2.5	5
581	Temporal sustainability of guideline based door-to-needle times for intravenous thrombolysis for acute ischemic stroke. Journal of Clinical Neuroscience, 2020, 74, 164-167.	1.5	5
582	Identifying and responding to trial implementation challenges during multisite clinical trials. Journal of Substance Abuse Treatment, 2020, 112, 63-72.	2.8	5
583	Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression. Journal of Affective Disorders, 2021, 291, 39-45.	4.1	5
584	Irritability as an independent predictor of concurrent and future suicidal ideation in adults with stimulant use disorder: Findings from the STRIDE study. Journal of Affective Disorders, 2021, 292, 108-113.	4.1	5
585	Fluoxetine and Oculomotor Activity during Sleep in Depressed Patients. Neuropsychopharmacology, 1995, 12, 159-165.	5.4	5
586	Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR). Journal of Clinical Psychiatry, 2018, 79, 41-47.	2.2	5
587	Biomarkers and the future of treatment for depression. Cerebrum: the Dana Forum on Brain Science, 2012, 2012, 6.	0.1	5
588	A primary care first (PCP-first) model to screen and treat depression: A VitalSign6 report from a second cohort of 32,106 patients. General Hospital Psychiatry, 2022, 74, 1-8.	2.4	5
589	Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory. Translational Psychiatry, 2022, 12, 16.	4.8	5
590	The current crisis of confidence in antidepressants. Journal of Clinical Psychiatry, 2011, 72, 27-33.	2.2	5
591	Alterations in resting-state functional activity and connectivity for major depressive disorder appetite and weight disturbance phenotypes. Psychological Medicine, 2023, 53, 4517-4527.	4.5	5
592	Montgomeryâ€Ã…sberg Depression Rating Scale factors in treatmentâ€resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine. International Journal of Methods in Psychiatric Research, 2022, 31, .	2.1	5
593	Datapoints: Rates of Nonfatal Intentional Self-Harm in Nine States, 2001. Psychiatric Services, 2006, 57, 313-313.	2.0	4
594	Effects of heart disease on depression treatment: results from the COMED study. General Hospital Psychiatry, 2012, 34, 24-34.	2.4	4

#	Article	IF	Citations
595	Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders. American Journal on Addictions, 2016, 25, 215-220.	1.4	4
596	Dose Response for SSRIs. American Journal of Psychiatry, 2016, 173, 105-106.	7.2	4
597	Antisuicidal Effects of Ketamine: A Promising First Step. American Journal of Psychiatry, 2018, 175, 97-98.	7.2	4
598	Experimental Therapies for Treatment-Resistant Depression: Deciding When to Go to an Unproven or Experimental Therapy. Focus (American Psychiatric Publishing), 2018, 16, 279-284.	0.8	4
599	When Discontinuing SSRI Antidepressants Is a Challenge: A Response to Letters to the Editor. American Journal of Psychiatry, 2019, 176, 488-489.	7.2	4
600	Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. Journal of Affective Disorders, 2020, 277, 478-485.	4.1	4
601	Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD. Kidney360, 2020, 1, 436-446.	2.1	4
602	Smoking status links habenular volume to glycated hemoglobin: Findings from the Human Connectome Project-Young Adult. Psychoneuroendocrinology, 2021, 131, 105321.	2.7	4
603	The Status of Evidence-Based Guidelines and Algorithms in the Treatment of Depression. Psychiatric Annals, 2002, 32, 658-663.	0.1	4
604	Inadequate Response to Antidepressant Treatment in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	2.2	4
605	How Can Measurement-Based Care Help Improve Treatment Outcomes for Major Depressive Disorder in Primary Care?. Journal of Clinical Psychiatry, 2020, 81, .	2.2	4
606	Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacology Bulletin, 2009, 42, 5-20.	0.0	4
607	Clinical significance of monitoring early symptom change to predict outcome. Journal of Clinical Psychiatry, 2001, 62 Suppl 4, 27-33; discussion 37-40.	2.2	4
608	Using treatment algorithms for the effective management of treatment-resistant depression. Journal of Clinical Psychiatry, 2001, 62 Suppl 18, 25-9.	2.2	4
609	Sensitizing clinicians and patients to the social and functional aspects of remission. Journal of Clinical Psychiatry, 2001, 62 Suppl 19, 32-5.	2.2	4
610	Pitfalls and Recommended Strategies and Metrics for Suppressing Motion Artifacts in Functional MRI. Neuroinformatics, 2022, 20, 879-896.	2.8	4
611	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. Journal of Psychiatric Research, 2022, 149, 243-251.	3.1	4
612	Youth Aware of Mental Health (YAM) Program With Texas Adolescents. Journal of Clinical Psychiatry, 2022, 83, .	2.2	4

#	Article	IF	Citations
613	Dr. McGrath and Colleagues Reply. American Journal of Psychiatry, 2007, 164, 524-524.	7.2	3
614	Do Geographic Regions with Higher Suicide Rates also have Higher Rates of Nonfatal Intentional Self-Harm?. Suicide and Life-Threatening Behavior, 2008, 38, 637-649.	1.9	3
615	Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 3001-3010.	2.2	3
616	The Stimulant Selective Severity Assessment: A replication and exploratory extension of the Cocaine Selective Severity Assessment. Substance Use and Misuse, 2019, 54, 351-361.	1.4	3
617	Acute and long-term cannabis use among stimulant users: Results from CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE) Randomized Control Trial. Drug and Alcohol Dependence, 2019, 200, 139-144.	3.2	3
618	The Adolescent Resilience Questionnaire: Validation of a Shortened Version in U.S. Youths. Frontiers in Psychology, 2020, 11, 606373.	2.1	3
619	Reply to: EEG-based model and antidepressant response. Nature Biotechnology, 2021, 39, 28-29.	17.5	3
620	Electronic Mental Health Screening in a Pediatric Heart Failure and Transplant Clinic. Journal of Clinical Psychology in Medical Settings, 2021, 28, 815-825.	1.4	3
621	Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. Journal of Affective Disorders, 2021, 282, 602-610.	4.1	3
622	Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study. Journal of Affective Disorders, 2021, 295, 1066-1071.	4.1	3
623	Challenges and Algorithm-Guided Treatment in Major Depressive Disorder. Journal of Clinical Psychiatry, 2011, 72, e14.	2.2	3
624	Voice response system to measure healthcare costs: a STAR*D report. American Journal of Managed Care, 2009, 15, 153-62.	1.1	3
625	Opioid addiction screening tools for patients with chronic noncancer pain. Texas Medicine, 2015, 111, 61-5.	0.0	3
626	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C5) and Self-Report (VQIDS-SR5) Versions of the Very Quick Inventory of Depressive Symptoms. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 289-302.	2.2	3
627	Occlusion of a tracheostomy tube after misinsertion. Anaesthesia, 2006, 61, 407-408.	3.8	2
628	Use of Decision Support Tools for Treatment Algorithms. CNS Spectrums, 2007, 12, 9-16.	1.2	2
629	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. Focus (American Psychiatric Publishing), 2008, 6, 104-119.	0.8	2
630	Anticipated Benefits of Care (ABC): psychometrics and predictive value in psychiatric disorders. Psychological Medicine, 2010, 40, 955-965.	4.5	2

#	Article	IF	Citations
631	Response to Blier Letter. American Journal of Psychiatry, 2012, 169, 95-96.	7.2	2
632	Understanding the Impact of Treatment on the Dimensions of Childhood Depression. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 160-166.	1.3	2
633	Psychosocial relationship status and quality as predictors of exercise intervention adherence and substance use outcomes: Results from the STRIDE (CTN-0037) study. Psychiatry Research, 2017, 254, 332-339.	3.3	2
634	Randomized, Double-Blind Study of Fixed-Dose Intranasal Esketamine Plus Oral Antidepressant vs. Active Control in Treatment-Resistant Depression. Journal of Affective Disorders, 2019, 254, 131-132.	4.1	2
635	Biomarker-Based Treatment Selection: A Precision Medicine Approach for Depression. , 2019, , 331-340.		2
636	Gender and racial/ethnic differences in physiologic responses in the Stimulant Reduction Intervention using Dosed Exercise Study. Addictive Behaviors, 2020, 110, 106546.	3.0	2
637	If there were an effective pharmacotherapy for cocaine use disorder, what would it do?. Addiction, 2021, 116, 714-715.	3.3	2
638	Psychometric Evaluation of the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire in a General Youth Population. Child Psychiatry and Human Development, 2021, , 1.	1.9	2
639	Identifying novel mechanisms and treatment targets for irritability and aggression in psychiatric disorders. Neuropsychopharmacology, 2022, 47, 420-421.	5.4	2
640	Do Depressed Patients With Diabetes Experience More Side Effects When Treated With Citalopram Than Their Counterparts Without Diabetes?. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 186-196.	0.6	2
641	Tackling Partial Response to Depression Treatment. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 155-162.	0.6	2
642	Treating Partial Responders to Antidepressant Treatment. Journal of Clinical Psychiatry, 2009, 70, e31.	2.2	2
643	Using Measurement-Based Care With Patient Involvement to Improve Outcomes in Depression. primary care companion for CNS disorders, The, 2013, 15, .	0.6	2
644	Functional neuroanatomy of obsessive-compulsive disorder. Journal of Clinical Psychiatry, 1996, 57 Suppl 8, 26-35; discussion 36.	2.2	2
645	Using treatment algorithms to bring patients to remission. Journal of Clinical Psychiatry, 2003, 64 Suppl 2, 8-13.	2.2	2
646	Remission of depression and the Texas Medication Algorithm Project. Managed Care Interface, 2003, Suppl B, 9-13.	0.2	2
647	Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2022, 63, 1347-1358.	5.2	2
648	Remission-Oriented Treatment of Depression. CNS Spectrums, 2001, 6, 1-12.	1.2	1

#	Article	IF	Citations
649	Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report. International Journal of Cognitive Therapy, 2009, 2, 66-87.	2.2	1
650	Release bias in accessing medical records in clinical trials: a STAR*D report. International Journal of Methods in Psychiatric Research, 2009, 18, 147-158.	2.1	1
651	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. Focus (American Psychiatric Publishing), 2012, 10, 492-505.	0.8	1
652	What Did STARâœ«D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. Focus (American Psychiatric Publishing), 2012, 10, 510-517.	0.8	1
653	The Effect of Antidepressant Therapy on Blood Pressure and Heart Rate Variability. Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies, 2013, 48, 1-7.	0.1	1
654	Optimization of Treatment Algorithms for Clinical Depression: Glutamate Antagonists and Transcranial Magnetic Stimulation as Case Examples. Focus (American Psychiatric Publishing), 2014, 12, 146-151.	0.8	1
655	The Treatment with Exercise Augmentation for Depression (TREAD) study. , 2016, , 96-108.		1
656	317. Screening for Auto-Antibodies with Antidepressant Medications Using Glomerular Proteomic Microarray Arrays: Findings from CoMed Clinical Trial. Biological Psychiatry, 2017, 81, S130-S131.	1.3	1
657	50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results. CNS Spectrums, 2019, 24, 203-204.	1.2	1
658	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. Focus (American) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382	0.8	1
659	Characterizing Cerebral Blood Perfusion and Treatment Outcomes in Atypical and Melancholic Depression. Biological Psychiatry, 2020, 87, S94.	1.3	1
660	Implementing mental health screening, assessment, and navigation program in a community-based survivorship program.. Journal of Clinical Oncology, 2017, 35, 36-36.	1.6	1
661	Dural venous sinus thrombosis following intravitreal bevacizumab. Neurology India, 2017, 65, 166.	0.4	1
662	Central disorders of hypersomnolence in children and adults: A comparative study from South India. Annals of Indian Academy of Neurology, 2019, 22, 442.	0.5	1
663	Pilot Studies to Evaluate Feasibility of a Physical Activity Intervention for Persons With Depression. Journal of Sport and Exercise Psychology, 2020, 42, 443-451.	1.2	1
664	Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. European Journal of Clinical Pharmacology, 2022, 78, 965-973.	1.9	1
665	A Characterization of the Clinical Global Impression Scale Thresholds in the Treatment of Adolescent Depression Across Multiple Rating Scales. Journal of Child and Adolescent Psychopharmacology, 2022, 32, 278-287.	1.3	1
666	Do Dual-Action Neurotransmitter Agents Offer an Advantage in Psychiatric Treatment?. CNS Spectrums, 2001, 6, 1-8.	1.2	0

#	Article	IF	Citations
667	Antecedentes familiares de suicidio consumado y caracterÃsticas del trastorno depresivo mayor: estudio STAR*D (sequenced treatment alternatives to relieve depression). Psiquiatria Biologica, 2008, 15, 195-201.	0.1	0
668	RESPONSE TO STANTON, REABURN, AND ROSENBAUM. Journal of Psychiatric Practice, 2013, 19, 272-273.	0.7	0
669	36. Inflammatory Biomarkers as Viable Moderators of Selecting between SSRI and Bupropion in Depressed Outpatients. Biological Psychiatry, 2017, 81, S15-S16.	1.3	0
670	939. Identifying Clinically Relevant Electroencephalography Coherence Patterns in Major Depressive Disorder: Results from the EMBARC Study. Biological Psychiatry, 2017, 81, S380.	1.3	0
671	843. Serum Metabolites as a Predictor of Antidepressant Responsiveness in the Co-Med Trial. Biological Psychiatry, 2017, 81, S341-S342.	1.3	0
672	Sensitivity of Derived Clinical Biomarkers to rs-fMRI Preprocessing Software Versions. , 2019, 2019, 1581-1584.		0
673	133. Baseline Functional Connectivity and Cerebral Perfusion Markers of Response to Sertraline Vs. Placebo: A Data-Driven Multi-Modal Neuroimaging Study. Biological Psychiatry, 2019, 85, S55-S56.	1.3	0
674	O14. Cerebral Blood Perfusion Predicts Response to Antidepressant Treatment in Major Depressive Disorder. Biological Psychiatry, 2019, 85, S111.	1.3	0
675	Exploring the Association of Sex Differences and Exposure to Maternal Smoking With Low Fetal Growth. JAMA Psychiatry, 2019, 76, 766.	11.0	0
676	T142. Insulin Resistance Impacts the Relationship of Depression Severity on Cognitive Control. Biological Psychiatry, 2019, 85, S184.	1.3	0
677	2019 Articles of Import and Impact. American Journal of Psychiatry, 2020, 177, 17-19.	7.2	0
678	119 Assessment of Health-Related Quality of Life and Health Status in Patients with Treatment-resistant Depression. CNS Spectrums, 2020, 25, 277-278.	1.2	0
679	181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder. CNS Spectrums, 2020, 25, 314-315.	1.2	0
680	180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. CNS Spectrums, 2020, 25, 313-314.	1.2	0
681	2020 Articles of Import and Impact. American Journal of Psychiatry, 2021, 178, 13-16.	7.2	0
682	Preliminary Evidence for Sociotropy and Autonomy in Relation to Antidepressant Treatment Outcome. Psychiatric Quarterly, 2021, 92, 1069-1077.	2.1	0
683	Addressing adherence to antidepressant treatment for depression. Revista Brasileira De Psiquiatria, 2021, 43, 125-126.	1.7	0
684	Neurocircuit Mechanisms of Active Suicidal Ideation in Youths and Young Adults: Findings From the T-Rad Study. Biological Psychiatry, 2021, 89, S82.	1.3	0

#	Article	IF	Citations
685	Whole-Transcriptome Brain Expression and Exon-Usage Profiling in Major Depression and Suicide. Biological Psychiatry, 2021, 89, S120-S121.	1.3	0
686	Irritability Partly Accounts for the Association Between Pain and Depression: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project. Biological Psychiatry, 2021, 89, S91.	1.3	0
687	Sex-Specific Differences in the Association Between Obesity and Depression in Large Epidemiological Studies: Findings From Dallas Heart Study and National Health and Nutrition Examination Survey. Biological Psychiatry, 2021, 89, S340.	1.3	0
688	Moderators of treatment response to exercise in participants with stimulant use disorder: Exploratory results from the Stimulant Reduction using Dosed Exercise (STRIDE)CTN-0037 study. Mental Health and Physical Activity, 2021, 21, 100421.	1.8	0
689	EXERCISE DOSE-RESPONSE AND CONTINUATION TREATMENT OF MAJOR DEPRESSION. Medicine and Science in Sports and Exercise, 2003, 35, S216.	0.4	0
690	Treatment-Refractory Depression. Handbook of Experimental Pharmacology, 2004, , 447-488.	1.8	0
691	Do depressed patients with diabetes experience more side effects when treated with CitalopramThan their counterparts without diabetes? a STAR*D study. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 186-96.	0.6	0
692	Algorithms in clinical psychiatry: a stepped approach toward the path to recovery. Psychopharmacology Bulletin, 2002, 36 Suppl 2, 142-9.	0.0	0
693	Accelerated Brain Aging in Major Depressive Disorder Predicts Poorer Treatment Outcomes with Sertraline: Findings From the EMBARC Study. Biological Psychiatry, 2022, 91, S4.	1.3	0